FORD OEM CK4Z1130C 4) of (Set Caps Wheels-Center Transit-150 15-18 Other Car & Truck Wheels, Tires & Parts


  1. Home
  2. FORD OEM CK4Z1130C 4) of (Set Caps Wheels-Center Transit-150 15-18
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
FORD OEM 15-18 Transit-150 Wheels-Center Caps (Set of 4) CK4Z1130C
Condition: New Genuine OEM: Yes
Fitment Type: Direct Replacement Warranty: 1 Year
Category 3: Covers & Trim Quantity: 1
Item Name: Center Cap SKU: FD:CK4Z-1130-C
Part Ref# on Diagram: ONLY PART REFERENCE #2 ON THE DIAGRAM IS INCLUDED Brand:

Ford

Quantity Needed: 1 Manufacturer Part Number:

CK4Z1130C

Category 1: Front Suspension Category 2: Wheels
UPC:

Does not apply



published on tue nov 09 2021

FORD OEM CK4Z1130C 4) of (Set Caps Wheels-Center Transit-150 15-18 Other Car & Truck Wheels, Tires & Parts

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

FORD OEM CK4Z1130C 4) of (Set Caps Wheels-Center Transit-150 15-18 Other Car & Truck Wheels, Tires & Parts

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS